TY - JOUR
T1 - Clinical determinants of elevated systolic pulmonary artery pressure measured by transthoracic Doppler echocardiography in early systemic sclerosis
AU - EUSTAR co-authors
AU - Carreira, Patricia E.
AU - Carmona, Loreto
AU - Joven, Beatriz E.
AU - Loza, Estibaliz
AU - Andreu, José Luis
AU - Riemekasten, Gabriela
AU - Vettori, Serena
AU - Allanore, Yannick
AU - Balbir-Gurman, Alexandra
AU - Airò, Paolo
AU - Walker, Ulrich A.
AU - Damjanov, Nemanja
AU - Ananieva, Lidia P.
AU - Rednic, Simona
AU - Czirják, László
AU - Distler, Oliver
AU - Farge, Dominique
AU - Hesselstrand, Roger
AU - Corrado, Ada
AU - Caramaschi, Paola
AU - Tikly, Mohammed
AU - Matucci-Cerinic, Marco
N1 - Funding Information:
The authors and all EUSTAR centres are grateful for the support of the European League Against Rheumatism until 2013. This work was partially supported by FIS grant 11/01506 from the Instituto de Salud Carlos III, Spain (Spanish Ministry of Economy and Competitiveness), and from an unrestricted grant from Merck Sharp and Dohme to the Instituto de Investigaci?n del Hospital 12 de Octubre, Madrid (2014 0062). EUSTAR was supported by the European League Against Rheumatism until 2013.
Publisher Copyright:
© Clinical and Experimental Rheumatology 2017.
Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2017/10/12
Y1 - 2017/10/12
N2 - Objective. To explore the prevalence and clinical associations of elevated systolic pulmonary artery pressure (sPAP), measured by Transthoracic Dopplerechocardiography (TTE) in patients with early systemic sclerosis (SSc). Methods. A cross-sectional analysis of the prospective EULAR Scleroderma Trial and Research (EUSTAR) database was performed. SSc patients with < 3 years from the first non-Raynaud's phenomenon (RP) symptom at baseline EUSTAR visit, were selected. Elevated sPAP was defined as sPAP > 40 mmHg on baseline TTE. First visit SSc related variables, including disease subsets, antibodies and visceral involvement, were examined. Results. From 1,188 patients, 81% were women. Mean (SD) age at first non-RP symptom was 50 (14) years, 55% had limited cutaneous SSc (lcSSc) and 42% active disease. Elevated sPAP was found in 17% of patients, both lcSSc and diffuse cutaneous SSc (dc- SSc). In lcSSc, older age at first non- RP symptom, ACA positivity, joint contractures, restrictive defect and lower DLCO, were independently associated with elevated sPAP. In dcSSc, older age at first non-RP symptom, longer time between RP onset and first non-RP symptom, digital ulcers, cardiac blocks, and proteinuria were associated with elevated sPAP. Conclusion. The prevalence of elevated sPAP on TTE in early SSc patients is considerable. Association with cardiac, lung and renal involvement suggests that, although some patients might have pulmonary arterial hypertension, others may present pulmonary hypertension secondary to lung or heart involvement. Our findings emphasise the need to consider right heart catheterisation in selected early SSc patients with PH suspicion, to clearly determine the cause of PH.
AB - Objective. To explore the prevalence and clinical associations of elevated systolic pulmonary artery pressure (sPAP), measured by Transthoracic Dopplerechocardiography (TTE) in patients with early systemic sclerosis (SSc). Methods. A cross-sectional analysis of the prospective EULAR Scleroderma Trial and Research (EUSTAR) database was performed. SSc patients with < 3 years from the first non-Raynaud's phenomenon (RP) symptom at baseline EUSTAR visit, were selected. Elevated sPAP was defined as sPAP > 40 mmHg on baseline TTE. First visit SSc related variables, including disease subsets, antibodies and visceral involvement, were examined. Results. From 1,188 patients, 81% were women. Mean (SD) age at first non-RP symptom was 50 (14) years, 55% had limited cutaneous SSc (lcSSc) and 42% active disease. Elevated sPAP was found in 17% of patients, both lcSSc and diffuse cutaneous SSc (dc- SSc). In lcSSc, older age at first non- RP symptom, ACA positivity, joint contractures, restrictive defect and lower DLCO, were independently associated with elevated sPAP. In dcSSc, older age at first non-RP symptom, longer time between RP onset and first non-RP symptom, digital ulcers, cardiac blocks, and proteinuria were associated with elevated sPAP. Conclusion. The prevalence of elevated sPAP on TTE in early SSc patients is considerable. Association with cardiac, lung and renal involvement suggests that, although some patients might have pulmonary arterial hypertension, others may present pulmonary hypertension secondary to lung or heart involvement. Our findings emphasise the need to consider right heart catheterisation in selected early SSc patients with PH suspicion, to clearly determine the cause of PH.
UR - http://www.scopus.com/inward/record.url?scp=85031665405&partnerID=8YFLogxK
M3 - Journal articles
C2 - 28664832
AN - SCOPUS:85031665405
SN - 0392-856X
VL - 35
SP - S114-S121
JO - Clinical and Experimental Rheumatology
JF - Clinical and Experimental Rheumatology
ER -